Animal Pharm's Top 20 – 2000 Edition
Company Analysis
Animal Pharm Reports provides you with a definitive guide to the key players driving the global animal health industry. It is an extensive review of the major animal health product manufacturers world-wide, enabling you to access and act upon the latest business intelligence.
Animal Pharm's Top 20 will tell you:
PUBLISHED: NOVEMBER 2000
REFERENCE: SR200E
PRICE: £395/$830/¥95,000
PAGES: 249
For further information about this report, please contact our Customer Helpdesk on:
Tel: +44 (0)20 8332 8965 / 66
Fax: +44 (0)20 8332 8992
E-mail: [email protected]
CONTENTS
LIST OF TABLES
LIST OF FIGURES
FOREWORD
ABBREVIATIONS
CHAPTER 1 - INTRODUCTION (12 pages)
1.1 The world market for animal health and nutrition products
1.2 Geography of the world market
1.3 World market structure
1.4 The animal health industry
1.5 Leading animal health and nutrition companies
1.5.1 Market leaders in 1999
1.5.2 Market leaders in 2000
1.6 Exchange rates
CHAPTER 2 - ALPHARMA (12 pages)
2.1 Company background
2.2 Animal health sales and operating profit
2.2.1 1998 performance
2.2.2 1999 performance
2.2.3 Interim 2000 performance
2.3 Geography of the business
2.3.1 Feed additives
2.3.2 Vaccines
2.4 Product portfolio
2.4.1 Feed additives
2.4.2 Vaccines
2.5 Research and development
2.6 Strategy
2.7 Prospects
CHAPTER 3 - AVENTIS ANIMAL NUTRITION (10 pages)
3.1 Company background
3.2 Animal nutrition sales
3.2.1 1998 performance
3.2.2 1999 performance
3.2.3 Interim 2000 performance
3.3 Geography of the business
3.3.1 Europe, Middle East and Africa
3.3.2 North America
3.3.3 Asia/Pacific
3.3.4 Latin America
3.4 Product portfolio
3.4.1 Vitamins
3.4.2 Methionine
3.4.3 Other products
3.5 Research and development
3.6 Strategy
3.7 Prospects
CHAPTER 4 - BASF (10 pages)
4.1 Company background
4.2 Animal nutrition sales
4.2.1 1998 performance
4.2.2 1999 performance
4.2.3 Interim 2000 performance
4.3 Geography of the business
4.3.1 Europe
4.3.2 The Americas
4.3.3 Asia/Pacific
4.4 Product portfolio
4.4.1 Vitamins
4.4.2 Amino acids
4.4.3 Carotenoids
4.4.4 Enzymes
4.5 Research and development
4.6 Strategy
4.7 Prospects
CHAPTER 5 - BAYER (14 pages)
5.1 Company background
5.2 Animal health sales
5.2.1 1998 performance
5.2.2 1999 performance
5.2.3 Interim 2000 performance
5.3 Geography of the business
5.3.1 North America
5.3.2 Europe
5.3.3 Asia
5.3.4 South America
5.4 Product portfolio
5.4.1 Antiparasitics
5.4.2 Antimicrobials
5.4.3 Biologicals
5.4.4 Other products
5.5 Research and development
5.6 Strategy
5.7 Prospects
CHAPTER 6 - BOEHRINGER INGELHEIM (12 pages)
6.1 Company background
6.2 Animal health sales
6.2.1 1998 performance
6.2.2 1999 performance
6.2.3 Interim 2000 performance
6.3 Geography of the business
6.3.1 North America
6.3.2 Europe
6.3.3 Other markets
6.4 Product portfolio
6.4.1 Pharmaceuticals and feed additives
6.4.2 Biologicals
6.5 Research and development
6.6 Strategy
6.7 Prospects
CHAPTER 7 - CEVA (8 pages)
7.1 Company background
7.2 Animal health sales
7.2.1 1998 performance
7.2.2 1999 performance
7.3 Geography of the business
7.3.1 European Union
7.3.2 International markets
7.4 Product portfolio
7.4.1 Pharmaceuticals
7.4.2 Vaccines
7.4.3 Nutritionals
7.5 Research and development
7.6 Strategy
7.7 Prospects
CHAPTER 8 - DAINIPPON (8 pages)
8.1 Company background
8.2 Animal health sales
8.2.1 1998-1999 performance
8.2.2 1999-2000 performance
8.3 Geography of the business
8.4 Product portfolio
8.4.1 Companion animal products
8.4.2 Food animal products
8.5 Research and development
8.6 Strategy
8.7 Prospects
CHAPTER 9 - DEGUSSA-HÜLS (8 pages)
9.1 Company background
9.2 Animal nutrition sales
9.2.1 1998 performance
9.2.2 1999 performance
9.2.3 Interim 2000 performance
9.3 Geography of the business
9.4 Product portfolio
9.4.1 Amino acids
9.4.2 Other products
9.5 Research and development
9.6 Strategy
9.7 Prospects
CHAPTER 10 - ELANCO (10 pages)
10.1 Company background
10.2 Animal health sales and operating income
10.2.1 1998 performance
10.2.2 1999 performance
10.2.3 Interim 2000 performance
10.3 Geography of the business
10.3.1 North America
10.3.2 Other markets
10.4 Product portfolio
10.4.1 Tylosin
10.4.2 Monensin
10.4.3 Tilmicosin
10.4.4 Other products
10.5 Research and development
10.6 Strategy
10.7 Prospects
CHAPTER 11 - FORT DODGE (10 pages)
11.1 Company background
11.2 Animal health sales
11.2.1 1998 performance
11.2.2 1999 performance
11.2.3 Interim 2000 performance
11.3 Geography of the business
11.3.1 The United States
11.3.2 International markets
11.4 Product portfolio
11.4.1 Biologicals
11.4.2 Antiparasitics
11.4.3 Other pharmaceuticals
11.5 Research and development
11.6 Strategy
11.7 Prospects
CHAPTER 12 - HOFFMANN-LA ROCHE (12 pages)
12.1 Company background
12.2 Animal health sales
12.2.1 1998 performance
12.2.2 1999 performance
12.2.3 Interim 2000 performance
12.3 Geography of the business
12.4 Product portfolio
12.4.1 Vitamins
12.4.2 Carotenoids
12.4.3 Feed enzymes
12.4.4 12.4.4 Other products
12.5 Research and development
12.6 Strategy
12.7 Prospects
CHAPTER 13 - IDEXX (10 pages)
13.1 Company background
13.2 Sales and income
13.2.1 1998 performance
13.2.2 1999 performance
13.2.3 Interim 2000 performance
13.3 Geography of the business
13.4 Product portfolio
13.4.1 Companion animal group
13.4.2 Food and environmental division
13.5 Research and development
13.6 Strategy
13.7 Prospects
CHAPTER 14 - INTERVET (14 pages)
14.1 Company background
14.2 Animal health sales
14.2.1 1998 performance
14.2.2 1999 performance
14.2.3 Interim 2000 performance
14.3 Geography of the business
14.3.1 Europe
14.3.2 Americas
14.3.3 Asia/Pacific
14.4 Product portfolio
14.4.1 Vaccines
14.4.2 Antiparasitics
14.4.3 Feed additives
14.4.4 Other pharmaceuticals
14.5 Research and development
14.6 Strategy
14.7 Prospects
CHAPTER 15 - MERIAL (14 pages)
15.1 Company background
15.2 Animal health sales
15.2.1 1998 performance
15.2.2 1999 performance
15.2.3 Interim 2000 performance
15.3 Geography of the business
15.3.1 North America
15.3.2 Europe
15.3.3 South America
15.3.4 Other markets
15.4 Product portfolio
15.4.1 Avermectins
15.4.2 Fipronil
15.4.3 Biologicals
15.4.4 Other products
15.5 Research and development
15.6 Strategy
15.7 Prospects
CHAPTER 16 - NOVARTIS (12 pages)
16.1 Company background
16.2 Animal health sales and operating profit
16.2.1 1998 performance
16.2.2 1999 performance
16.2.3 Interim 2000 performance
16.3 Geography of the business
16.3.1 The Americas
16.3.2 Europe
16.3.3 Other markets
16.4 Product portfolio
16.4.1 Antiparasitics
16.4.2 Feed additives
16.4.3 Other pharmaceuticals
16.4.4 Vaccines
16.5 Research and development
16.6 Strategy
16.7 Prospects
CHAPTER 17 - PFIZER (16 pages)
17.1 Company background
17.2 Animal health sales and operating profit
17.2.1 1998 performance
17.2.2 1999 performance
17.2.3 Interim 2000 performance
17.3 Geography of the business
17.3.1 The United States
17.3.2 International markets
17.4 Product portfolio
17.4.1 Antiparasitics
17.4.2 Biologicals
17.4.3 Anti-infectives
17.4.4 Other pharmaceuticals
17.4.5 Feed additives
17.5 Research and development
17.6 Strategy
17.7 Prospects
CHAPTER 18 - PHARMACIA (10 pages)
18.1 Company background
18.2 Animal health sales
18.2.1 1998 performance
18.2.2 1999 performance
18.2.3 Interim 2000 performance
18.3 Geography of the business
18.3.1 North America
18.3.2 Europe
18.3.3 Other markets
18.4 Product portfolio
18.4.1 Ceftiofur
18.4.2 Lincomycin and spectinomycin
18.4.3 Other P&U products
18.4.4 Posilac
18.5 Research and development
18.6 Strategy
18.7 Prospects
CHAPTER 19 - SCHERING-PLOUGH (10 pages)
19.1 Company background
19.2 Animal health sales
19.2.1 1998 performance
19.2.2 1999 performance
19.2.3 Interim 2000 performance
19.3 Geography of the business
19.4 Product portfolio
19.4.1 Antiparasitics
19.4.2 Anti-infectives
19.4.3 Biologicals
19.4.4 Other products
19.5 Research and development
19.6 Strategy
19.7 Prospects
CHAPTER 20 - VÉTOQUINOL (8 pages)
20.1 Company background
20.2 Animal health sales
20.2.1 1998 performance
20.2.2 1999 performance
20.2.3 Interim 2000 performance
20.3 Geography of the business
20.3.1 Europe
20.3.2 North America
20.3.3 Other markets
20.4 Product portfolio
20.4.1 Anti-infectives
20.4.2 Biologicals
20.4.3 Other products
20.5 Research and development
20.6 Strategy
20.7 Prospects
CHAPTER 21 - VIRBAC (10 pages)
21.1 Company background
21.2 Animal health sales and operating profit
21.2.1 1998 performance
21.2.2 1999 performance
21.2.3 Interim 2000 performance
21.3 Geography of the business
21.3.1 Europe
21.3.2 North America
21.3.3 South America
21.3.4 Other markets
21.4 Product portfolio
21.4.1 Antiparasitics
21.4.2 Anti-infectives
21.4.3 Biologicals
21.4.4 Other products
21.5 Research and development
21.6 Strategy
21.7 Prospects
FOREWORD
The 2000 edition of Animal Pharm's Top 20 report has been updated to reflect the performance of animal health and nutrition industry leaders through 1999 and the first half of 2000. As in previous editions, each company profile contains background information on parent companies and corporate strategies, which continue to exert a major impact on the shape of the animal health industry.
Each profile also tracks animal health company sales performances (and, where figures are available, profit) through the period from 1994 to 1999. The shape of individual businesses is analysed in both geographical and product terms, and R&D activity is also discussed. Finally, individual animal health company strategies are outlined and future prospects for each business are discussed.
The introductory section of the report includes updated information on the size and structure of the world market for animal health and nutrition products. It also contains details of the merger and acquisition (M&A) activity that continues to be a feature of the sector. Animal health company sales rankings are provided, based on actual sales figures for 1999 and Animal Pharm forecasts for 2000. Unless otherwise stated, currency conversions used in the report have been calculated at annual average rates for the years in question. Dollar sales forecasts for 2000 have been converted at rates prevailing on 7 September 2000 (all relevant conversion rates are illustrated in Table 1.8).
Fluctuating currency exchange rates have had a particularly strong impact on sales figures reported by many companies in 2000 – largely as a result of the strength of the US dollar and the weakness of the euro. The fledgling European currency has been particularly weak, inflating significantly the interim sales reported by most European companies. The continued volatility of major currency exchange rates will affect sales forecasts for 2000, and dollar forecast figures are best used only for comparative purposes. Forecasts in local currencies offer a more accurate indication of how individual companies are expected to perform through the year as a whole.
© PJB Publications Ltd. 2000 All rights reserved. |